Health Condition 1: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Blood sampling at two time points: Trough and mid dose blood samples of ICU patients on Meropenem will be taken under strict aseptic precautions
Sponsors
JIPMER, PUDUCHERRY
Eligibility
Inclusion criteria
Inclusion criteria: Patients admitted in the intensive care units and receiving meropenem for at least two days (at least 5 doses completed) with sequential organ function assessment (SOFA score greater than or equal to 3)
Exclusion criteria
Exclusion criteria: Pregnant/ lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the proportion of patients in ICU achieving PKPD targets (100% fT above 4xMIC / 50% fT above 4xMICTimepoint: Trough concentration (right before the administration of the next dose) and Mid dose concentration (at 4th hour of 8th hourly drug administration regime) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the influence of factors like age, body weight, creatinine clearance, disease severity, & concomitant medications on the steady state trough concentrations of meropenem. 2. To study the association of meropenem PK/PD target achievement with clinical response & length of ICU stay. 3. To study the association of meropenem PK/PD target achievement with adverse effects like new onset acute kidney injury & seizures. Timepoint: Clinical response will be assessed at Day 10 | — |
Countries
India
Contacts
Public ContactDr Mirnalini A
JIPMER, PUDUCHERRY
Outcome results
None listed